



PRESS RELEASE – LIFE SCIENCES and BIOTECHNOLOGY

Leuven, Belgium – 18 November 2009

reMYND receives license renewal from Schering-Plough for RadarScreen

reMYND NV ('reMYND') announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic compounds in early stage drug discovery.

RadarScreen allows high-throughput identification of genotoxic liabilities, such as the induction of chromosomal breaks and DNA mutations, of compounds and their corresponding metabolites. It is a yeast-based technology comprising a fast, reproducible and highly robust enzymatic assay for cost-effective screening in a standard laboratory environment. In contrast with currently available tests, these characteristics permit extensive genotoxicity assessments early in the development process, already at the hit identification stage. As such RadarScreen provides guidance to chemical optimization and may prevent later stage failures. reMYND has developed and validated RadarScreen over the past few years and is licensing-out this technology to the pharma, biotech, food, environmental, cosmetics and chemical industries. reMYND is currently also developing ready-to-use kits in the form of 384-well-plates in collaboration with BioPredic International, based in France.

According to An Tanghe, reMYND's Business Developer, *"RadarScreen has been developed by reMYND's scientists to address a clear need: the ability to screen for genotox liabilities early in reMYND's own drug discovery process. The promising validation data obtained in-house and at Schering-Plough have triggered the decision to out-license the technology. Schering-Plough has been using RadarScreen for one year now and we are delighted about their enthusiasm. I have a firm belief, though, that not only the pharmaceutical industry can benefit from using RadarScreen. There are ample other industries for which elimination of genotoxic compounds at an early stage is essential, for instance food, environmental and cosmetics. Moreover, RadarScreen can play a pivotal role in helping the chemical industry to comply with the recently introduced REACH-legislation that gives greater responsibility to industry to manage the risks from chemicals and provide safety information on the substances"*

For more info, please contact:

NV reMYND

Dr. An Tanghe

Business Developer Contract Research

Tel: +32 16 75 14 22

Fax: +32 16 75 14 21

radarscreen@remynd.be

<http://www.remynd.com>



Notes for the editor:

About reMYND NV

reMYND NV, based in Leuven, Belgium, actively drives the development of disease modifying treatments against Alzheimer's Disease and Parkinson's Disease, either through its own Drug Discovery&Development (DDD) or as a Contract Research Organization (CRO). reMYND NV is privately owned and was founded in 2002 as a spin-off of the University of Leuven. The CRO mainly focuses on Alzheimer transgenic mouse models with amyloid (APP London mutation) and/or Tau pathology. The DDD Unit focuses on Tau (AD) and α -synuclein (PD) as targets. The lead PD program is ready to enter Phase 1, while the lead AD program is planned to enter clinical testing in 2011.

About Biopredic International

Biopredic International, based in Rennes, France, is a provider of ethically-obtained and difficult to locate human and animal cells, tissue, and blood used in discovery and development of drugs, including very unique human liver cells such as the HepaRG® cells and primary hepatocytes, human skin sheets and human bio-fluids.

About FlandersBio

FlandersBio supports the release of biotech news, to inform the media about the press releases of its members, active in the sector.

FlandersBio is the umbrella organisation for the Life Sciences sector in Flanders, a dynamic non-profit, fee based organisation with 160 members. Our mission is to support and facilitate the sector's sustained development. Our objective is to ensure that it remains a strong driver of economic growth in the region. The FlandersBio network brings together companies with innovative, R&D-driven activities in the life sciences – companies that are for example developing biopharmaceuticals, medical technologies or agricultural or industrial biotech products. Our network welcomes companies with production activities based in Flanders as well as academic research institutes and providers of capital, services and technologies to the life sciences community.

Disclaimer

FlandersBio is not responsible for the content of this press release. In no event shall FlandersBio be liable for any incidental or consequential damages, even if FlandersBio has been informed of the possibility thereof.